Company profile
NEXTCURE, INC.
NASDAQ:NXTCBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| NC-410 | phase1_2 | — | 2 | terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06774963 | phase1 | recruiting | 2025-01-07 | 2026-12-01 | NextCure, Inc. | A Phase 1 Study of LNCB74 in Advanced Solid Tumors |
| NCT06792552 | phase1 | recruiting | 2025-02-26 | 2028-02-01 | NextCure, Inc. | A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors |
| NCT04430933 | phase1_2 | withdrawn | 2021-12-06 | 2022-06-30 | NextCure, Inc. | A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC |
| NCT03665285 | phase1_2 | completed | 2018-10-01 | 2023-04-11 | NextCure, Inc. | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors |
| NCT04408599 | phase1_2 | terminated | 2020-06-10 | 2023-07-06 | NextCure, Inc. | A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors |
FDA applications (0)
No records yet.